Calabrese, V., Cornelius, C., Stella, A
Capmatinib (INC280) is active against models of nonsmall cell lung cancer and other cancer types with defined mechanisms of MET activation
Understanding the broad mechanism of action is essential when considering whether GLP-1 medications might influence hormonal balance more generally, particularly given their increasing use in diverse patient populations including those with metabolic syndrome, polycystic ovary syndrome (PCOS), and obesity-related endocrine dysfunction
It contains the same active ingredient at a fraction of the cost, making it a more accessible choice for eligible patients
Circadian Rhythms of Plasma Renin Activity and Aldosterone: Changes Related to Age, Sex, Recumbency and Sodium Restriction